Supplementary Materials

Supplementary Material for:

TGF-β Signaling Mediates Endothelial-to-Mesenchymal Transition (EndMT) During Vein Graft Remodeling

Brian C. Cooley, Jose Nevado, Jason Mellad, Dan Yang, Cynthia St. Hilaire, Alejandra Negro, Fang Fang, Guibin Chen, Hong San, Avram D. Walts, Robin L. Schwartzbeck, Brandi Taylor, Jan D. Lanzer, Andrew Wragg, Abdalla Elagha, Leilani E. Beltran, Colin Berry, Robert Feil, Renu Virmani, Elena Ladich, Jason C. Kovacic, Manfred Boehm*

*Corresponding author. E-mail:

Published 12 March 2014, Sci. Transl. Med. 6, 227ra34 (2014)
DOI: 10.1126/scitranslmed.3006927

This PDF file includes:

  • Materials and Methods
  • Fig. S1. Endothelial cell lineage tracing and kinetics during vein graft remodeling.
  • Fig. S2. FACS analyses for YFP+ KSL (cKit+, Sca1+, Lin) hematopoietic stem cells.
  • Fig. S3. YFP+ cells in the neointima of EndotrackYFP grafted into wild-type recipients are not bone marrow–derived.
  • Fig. S4. FACS analysis of EndMT during vein graft remodeling.
  • Fig. S5. Vascular smooth muscle–specific recombination efficiency in Ind.SMCtrackYFP veins.
  • Fig. S6. Immunostaining using fibroblast and myofibroblast markers.
  • Fig. S7. Extracellular matrix proteins and mesenchymal markers in grafted jugular veins.
  • Fig. S8. Evidence of TGF-β signaling in EndMT at various time points in EndotrackYFP grafted veins.
  • Fig. S9. Localization of TGF-β–regulated transcription factors during vein graft remodeling.
  • Fig. S10. In vitro EndMT in mouse cells.
  • Fig. S11. TGF-β–Smad2/3 signaling activates EndMT in murine endothelial cells.
  • Fig. S12. TGF-β neutralizing antibody attenuates Smad2/3 activation.
  • Fig. S13. Knockdown of Smad3 or Smad2 attenuates neointimal formation.
  • Fig. S14. Smad3 and Smad1/5/8 presence 7 days after vein grafting.
  • Fig. S15. Expression of TGF-βR and TGF-β–induced gene targets in HUVECs.
  • Table S1. Primers used.
  • Table S2. Antibodies used.

[Download PDF]